Targeting a transcriptional scleraxis to treat cardiac fibrosis
- PMID: 36342270
- DOI: 10.1093/eurheartj/ehac608
Targeting a transcriptional scleraxis to treat cardiac fibrosis
Conflict of interest statement
Conflict of interest: T.A.M. is on the scientific advisory boards of Artemes Bio, Inc., and Eikonizo Therapeutics; has received funding from Italfarmaco for an unrelated project; and has a subcontract from Eikonizo Therapeutics related to an SBIR grant from the National Institutes of Health (HL154 959).
Comment on
-
Scleraxis and fibrosis in the pressure-overloaded heart.Eur Heart J. 2022 Dec 1;43(45):4739-4750. doi: 10.1093/eurheartj/ehac362. Eur Heart J. 2022. PMID: 36200607
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
